未知生产厂商
AZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.
AZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.
AZD3355 is reflux inhibitors which offer a new approach to the treatment of Gastroesophageal reflux disease (GERD) by improving the function of the lower oesophageal sphincter (LOS) through receptors responsible for opening and closing the sphincter.
Investigated for use/treatment in gastroesophageal reflux disease (GERD).
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
